Moreover, melanomas respond to immunotherapy with monoclonal antibodies that block the immune checkpoint receptors cytotoxic T-lymphocyte antigen 4 (CTLA4), such as ipilimumab, and programmed cell death protein 1 (PD1), such as pembrolizumab and nivolumab [1]. The gene discussed is PDCD1; the disease is melanoma.